Synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer agents by Johnson-Ajinwo, OR et al.
  
Proceedings 2019, 22, 42; doi:10.3390/proceedings2019022042 www.mdpi.com/journal/proceedings 
Abstract 
Synthesis and Evaluation of Thymoquinone 
Analogues as Anti-Ovarian Cancer Agents † 
Okiemute Rosa Johnson-Ajinwo 1,2, Alan Richardson 1 and Wen-Wu Li 1,* 
1 School of Pharmacy and Bioengineering, Keele University, ST4 7QB, Stoke-on-Trent, UK 
2 Faculty of Pharmaceutical Sciences, University of Port Harcourt, Port Harcourt, PMB 5323, Nigeria 
* Correspondence: w.li@keele.ac.uk  
† Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in 
Drug Discovery, Barcelona, Spain, 15–17 May 2019. 
Published: 8 August 2019 
Keywords: ovarian cancer; thymoquinone; nigella sativa; structure activity relationship 
 
Thymoquinone (TQ), 2-isopropyl-5-methyl-1,4-benzoquinone, a natural product isolated from 
Nigella sativa L., has previously been demonstrated to exhibit antiproliferative activity in vitro 
against a range of cancers, including ovarian, prostate, colon, breast, pancreatic cancers, leukaemia, 
and osteosarcoma [1–3]. Recently, TQ has been shown to block substrate recognition by the Polo-Box 
domain of Polo-like-kinase 1 (Plk1), a mitotic regulator that when overexpressed causes cancer [4]. 
We describe here the synthesis of a series of analogues of TQ that explore the potential for 
nitrogen-substitution to this scaffold, or reduction to a hydroquinone scaffold, in increasing the 
potency of its antiproliferative activity against ovarian cancer cell lines. In addition, alkyl or 
halogen-substituted analogues of TQ were commercially sourced and tested in parallel. Several TQ 
analogues with improved potency against ovarian cancer cells were found, although this increase 
was moderate. Key aspects of the structure activity relationship that could be further explored are 
highlighted [5]. In particular, a synthetic aminothymoquinone obtained via substitution of the CH of 
the isopropyl group in TQ by a single nitrogen atom showed significant improvement of water 
solubility, and synergism with two clinically used ovarian cancer drugs, carboplatin and paclitaxel. 
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